Eli Lilly and Elektrofi Entered into a Collaboration and License Agreement to Develop Patient-Centric Subcutaneous Therapies
Shots:
- As per the terms of the agreement, Elektrofi will receive an up front payment of $20M & is eligible to receive up to $750M which includes $150M as development, regulatory, & commercial milestones for each target plus mid-single-digit tiered royalties
- In return, Eli Lilly will receive the worldwide rights to develop & commercialize subcutaneous therapies for three targets by leveraging Elektrofi’s microparticle suspension technology platform for the treatment of cancer, autoimmune & neurologic disease
- Eli Lilly also has the option to pull two additional targets under its umbrella for additional payment and thereby will be responsible for the clinical development & commercialization of each product
Ref: Globenewswire | Image: Eli Lilly
Related News:- Eli Lilly Reports P-III Study (VIVID-1) Results of Mirikizumab for the Treatment of Crohn's Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
